SQZ Biotech, a Boston, MA-based developer of cell engineering technology that harnesses the body’s natural immune system to combat disease, raised $4m in Series B funding.
Quark Venture made the investment joining GV, NanoDimension, Polaris Partners and others.
The company intends to use the funds to further invest in the platform and advance its preclinical immuno-therapy programs in oncology and other serious diseases.
Originated out of Dr. Klavs Jensen and Robert Langer’s laboratories at the Massachusetts Institute of Technology (MIT) in Boston, and led by Armon Sharei, Co-Founder and Chief Executive Officer, SQZ Biotech provides CellSqueeze, whose cell engineering capabilities are being used to develop innovative cell therapies to combat disease across a broad range of indications.
FinSMEs
01/12/2016